Where can I find news about CRIS?

The latest headlines, third-party analysis, and SEC filings for Curis, Inc. (CRIS) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.

Where are CRIS's SEC filings?

Curis, Inc. (CRIS)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

Where are CRIS's earnings call transcripts?

Full earnings call transcripts for Curis, Inc. (CRIS) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

CRIS

Curis, Inc.

NASDAQ·Biotechnology · Healthcare

$1.54$0.05−3.14%

After hours·$1.53−0.65%

Market cap$3.00M·Market closed·Aug 26 8:00 PM UTC

News & Analysis

Curis, Inc. Announces Pricing of $5.6 Million Public Offering
LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the Company (or pre-funded warrants to purchase shares of common stock in lieu thereof) and warrants to purchase up to 3,733,334 shares of common stock at a combined public offering price of $1.50 per share and accompanying common warrant (or a combined public offering price of $1.49 per pre-funded warrant and accompanying common warrant) (the "Offering").
prnewswire.comAug 13, 2026 · 8:00 AM
Curis Doses First Five Patients in TakeAim CLL Study
LEXINGTON, Mass., July 30, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment milestone in its TakeAim CLL study in patients with Chronic Lymphocytic Leukemia (CLL).
prnewswire.comJul 30, 2026 · 8:00 AM
Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus
On Wednesday, Curis Inc. (NASDAQ:CRIS) announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance.
benzinga.comJul 24, 2026 · 2:03 PM
Curis, Inc. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma Transcript
Curis, Inc. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma Transcript
seekingalpha.comJul 22, 2026 · 1:50 PM
Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates
Curis Inc. (NASDAQ:CRIS) on Wednesday announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance.
benzinga.comJul 22, 2026 · 1:04 PM
Curis Announces Positive Emavusertib Update
Updated Clinical Data in PCNSL Increased Guidance on Year-End Data in CLL Company to Host Webcast at 8:30 a.m. ET LEXINGTON, Mass.
prnewswire.comJul 22, 2026 · 7:00 AM
Curis Consents First Six Patients in TakeAim CLL Study
LEXINGTON, Mass., July 6, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment milestone in its TakeAim CLL study.
prnewswire.comJul 6, 2026 · 9:30 AM
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split
Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Rever
gurufocus.comJun 26, 2026 · 10:00 AM

SEC Filings

424B4
Aug 13, 2026View on SEC
EFFECT
Aug 13, 2026View on SEC
S-1
Aug 10, 2026View on SEC
8-K
Jul 30, 2026View on SEC
8-K
Jul 2, 2026View on SEC
8-K/A
Jul 1, 2026View on SEC

Frequently Asked Questions About CRIS

Where can I find news about CRIS?: The latest headlines, third-party analysis, and SEC filings for Curis, Inc. (CRIS) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.
Where are CRIS's SEC filings?: Curis, Inc. (CRIS)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
Where are CRIS's earnings call transcripts?: Full earnings call transcripts for Curis, Inc. (CRIS) — prepared remarks plus speaker-by-speaker analyst Q&A — live on the Earnings tab, alongside the Earnings Reports section that links each quarter's press release and SEC report.

Curis, Inc.

Frequently Asked Questions About CRIS

Curis, Inc.

Curis, Inc. Announces Pricing of $5.6 Million Public Offering

Curis Doses First Five Patients in TakeAim CLL Study

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus

Curis, Inc. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma Transcript

Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates

Curis Announces Positive Emavusertib Update

Curis Consents First Six Patients in TakeAim CLL Study

Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split

Frequently Asked Questions About CRIS

Curis, Inc. Announces Pricing of $5.6 Million Public Offering

Curis Doses First Five Patients in TakeAim CLL Study

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus

Curis, Inc. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma Transcript

Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates

Curis Announces Positive Emavusertib Update

Curis Consents First Six Patients in TakeAim CLL Study

Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split